Candel Therapeutics (NASDAQ:CADL - Get Free Report)'s stock had its "buy" rating reissued by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $11.00 price objective on the stock. HC Wainwright's price target would suggest a potential upside of 178.48% from the stock's current price.
Candel Therapeutics Stock Up 3.9 %
Shares of CADL stock traded up $0.15 during trading hours on Monday, hitting $3.95. 371,728 shares of the company were exchanged, compared to its average volume of 1,809,158. The company has a market capitalization of $126.72 million, a PE ratio of -2.34 and a beta of -0.88. Candel Therapeutics has a 52 week low of $0.77 and a 52 week high of $14.30. The business has a 50 day moving average of $6.06 and a two-hundred day moving average of $6.76. The company has a current ratio of 1.62, a quick ratio of 1.62 and a debt-to-equity ratio of 1.66.
Insider Buying and Selling
In related news, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the firm's stock in a transaction on Monday, October 14th. The shares were sold at an average price of $6.02, for a total value of $90,300.00. Following the completion of the transaction, the insider now owns 929,873 shares of the company's stock, valued at approximately $5,597,835.46. This trade represents a 1.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders sold 31,800 shares of company stock worth $193,380. 41.60% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Candel Therapeutics
Hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp acquired a new position in Candel Therapeutics during the second quarter valued at approximately $338,000. Geode Capital Management LLC raised its stake in shares of Candel Therapeutics by 12.8% during the 3rd quarter. Geode Capital Management LLC now owns 448,997 shares of the company's stock worth $3,112,000 after purchasing an additional 51,111 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Candel Therapeutics in the 2nd quarter valued at approximately $162,000. Rhumbline Advisers bought a new position in shares of Candel Therapeutics in the second quarter valued at $143,000. Finally, Barclays PLC increased its holdings in Candel Therapeutics by 327.1% during the third quarter. Barclays PLC now owns 28,688 shares of the company's stock worth $199,000 after buying an additional 21,971 shares during the last quarter. Institutional investors own 13.93% of the company's stock.
About Candel Therapeutics
(
Get Free Report)
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
See Also
Before you consider Candel Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Candel Therapeutics wasn't on the list.
While Candel Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
